{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000138","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.443166+00:00","generated_at":"2026-05-30T15:08:33.361690+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC","bullets":["Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.","Merck supplies KEYTRUDA and sponsors one RCC phase 3; Exelixis co-funds phase 1/2 and other phase 3, supplies zanzalintinib and cabozantinib.","Exelixis retains all global commercial and marketing rights to zanzalintinib."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000138","json":"https://secwatch.observer/filing/0000939767-24-000138.json","markdown":"https://secwatch.observer/filing/0000939767-24-000138.md","text":"https://secwatch.observer/filing/0000939767-24-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/0000939767-24-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/exel-20241014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:08:33.361690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}